{"id":"W4253587619","doi":"10.1182/blood.v114.22.3851.3851","title":"A Phase I Clinical Trial Testing the Combination of Bortezomib and Tipifarnib in Relapsed/Refractory Multiple Myeloma.","year":2009,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; Proteasome inhibitor; Multiple myeloma; Internal medicine; Pharmacology; Refractory (planetary science); Lenalidomide; Oncology; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001374531,0.001964737,0.002220914,0.0006660952,0.0005106486,0.0009024647,0.001098718,0.001498151,0.004862537],"category_scores_gemma":[0.0005879684,0.000838465,0.0009227581,0.0004614928,0.001034867,0.000774499,0.0004139478,0.003046184,0.001317417],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009422276,"about_ca_system_score_gemma":0.001397983,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008741645,"about_ca_topic_score_gemma":0.002182319,"domain_scores_codex":[0.9995844,0.0001532289,0.00002183183,0.00007387649,0.00004400287,0.0001227053],"domain_scores_gemma":[0.9994749,0.00004934894,0.00007471926,0.00003523434,0.0000229632,0.0003427639],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6656628,0.1053476,0.005922825,0.0009413872,0.001018916,0.0008421529,0.0002884374,0.002990369,0.08114217,0.000548319,0.009225108,0.12607],"study_design_scores_gemma":[0.5353385,0.4504285,0.005364234,0.00002786335,0.0002640235,0.000355066,0.00003386896,0.0009461666,0.003932772,0.0001886313,0.00309211,0.00002822973],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.977981,0.00435126,0.0009786199,0.00125723,0.000325279,0.006752793,0.001916899,0.0002937432,0.006143201],"genre_scores_gemma":[0.9761649,0.002672803,0.003795269,0.001598949,0.0003692766,0.006061423,0.003027759,0.0000449182,0.006264792],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004862537,"threshold_uncertainty_score":0.01626682,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0980473417023826,"score_gpt":0.3940497644056899,"score_spread":0.2960024227033073,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}